Axsome Therapeutics — Third Quarter 2026 Earnings Summary

Axsome Therapeutics reported third-quarter 2026 total net product revenue of $259.7 million, marking a 52% year-over-year increase driven by strong sales of AUVELITY, SUNOSI, and SYMBRAVO. The company achieved a net loss of $12.9 million for the quarter, with cash and cash equivalents totaling $313.9 million as of September 30, 2026. Commercially, AUVELITY prescriptions grew 40% year-over-year, while the company initiated the SUMMIT Phase 3 trial for its smoking cessation candidate AXS-05. Additionally, the FDA PDUFA target date for the narcolepsy treatment AXS-12 is set for May 1, 2027, with multiple other Phase 3 trial results anticipated throughout 2027.